ERBB2 and breast cancer: Table 4 shows that the adjusted HR for OS was similar to that of the entire cohort with a value of 2.30 (95% CI = 1.99–2.66). The corresponding 7-year OS was 96.7% in patients with ES-TNBC vs. 93.2% in patients with LA-HR+/HER2- BC (Figure 2).